DSIP Benefits: What Studies Report

What this page does and does not do

This page organises, by outcome domain, what published papers on delta sleep-inducing peptide (DSIP) actually measured and reported. It is a map of an evidence base, not a list of effects a person should expect. Most of the literature summarised below used rodents, and several studies used modified versions of the peptide — a phosphorylated form, a fusion construct, or a structurally related analogue — rather than native DSIP. Where that is the case, it is labelled, because findings with a modified molecule do not automatically transfer to the parent peptide.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any health question or any decision involving an investigational substance. DSIP is not an approved drug product in the United States, and peptide material sold for laboratory work is labelled research-use-only.

Evidence at a glance

Sleep: the domain the peptide is named for

The name "delta sleep-inducing peptide" comes from early sleep research, and sleep remains the outcome most often searched for. Two papers in this citation set addressed it directly, and both used engineered forms of the peptide.

A fusion peptide in a chemically induced insomnia model

A 2024 paper in Frontiers in Pharmacology examined peptides secreted from Pichia pastoris that crossed the blood–brain barrier and tested a DSIP fusion peptide in PCPA-induced insomnia mouse models, reporting efficacy in that model (PMID 39444618). Two details matter for interpretation: PCPA (para-chlorophenylalanine) produces insomnia by depleting serotonin, which is a pharmacological model rather than a reproduction of human insomnia disorder, and the molecule tested was a fusion construct designed for delivery, not native DSIP (PMID 39444618).

Sleep architecture under hypoxic stress

A 2018 Life Sciences study reported that phosphorylated DSIP restored spatial memory and p-CREB expression by improving sleep architecture at high altitude (PMID 30107169). Here the sleep outcome was measured as an intermediate: researchers linked the improvement in sleep architecture to downstream changes in a memory-related signalling protein, p-CREB, and to spatial memory performance (PMID 30107169). The stressor was hypobaric hypoxia, not ordinary sleep disturbance, and again the peptide was a phosphorylated derivative (PMID 30107169).

Taken together, the sleep-related evidence in this set is preclinical and uses modified peptides; neither the mouse insomnia model work (PMID 39444618) nor the high-altitude study (PMID 30107169) was a controlled trial in people with a sleep disorder.

Cognition and memory

Memory appears in this literature as a secondary readout rather than a standalone target. The 2018 high-altitude study reported restoration of spatial memory alongside p-CREB expression, and attributed the cognitive change to improved sleep architecture rather than to a direct nootropic action (PMID 30107169). That is a mechanistic claim made inside an animal experiment; it does not establish that the peptide changes memory in healthy humans, and no human cognitive trial appears in this citation set.

Ischaemia, stroke and cardiac injury

Two experimental papers examined tissue injury after interrupted blood flow. A 2021 study in Molecules reported that DSIP recovered motor function in Sprague-Dawley rats after focal stroke (PMID 34500605). A companion line of work in Biomedicines reported that a DSIP-like KND peptide reduced brain infarction in C57Bl/6 mice and reduced myocardial infarction in Sprague-Dawley rats when administered during reperfusion (PMID 33918965).

The timing detail in the second study is important: the peptide was given during reperfusion, that is, at the moment blood flow was restored in an acute experimental injury (PMID 33918965). That is an acute-care research question, not a statement about general cardiovascular or neurological health. The KND peptide is also described as DSIP-like, so its results stand for that analogue (PMID 33918965), while the motor-recovery result stands for DSIP in a rat stroke model (PMID 34500605).

Seizure activity

A 2006 paper in Acta Physiologica Hungarica compared valproate and delta-sleep peptide against metaphit-induced audiogenic seizure in rats and reported high efficacy for both (PMID 17191662). Metaphit-induced audiogenic seizure is a specific chemically provoked convulsion model in rodents; the comparison with an established anticonvulsant is informative about the model but does not make the peptide an anti-seizure treatment in humans (PMID 17191662). No clinical epilepsy trial appears in this citation set.

Visceral and inflammatory models: acute pancreatitis

A 2002 Russian-language report in Eksperimental'naia i klinicheskaia farmakologiia described the pharmacological efficacy of delta sleep-inducing peptide in experimental acute pancreatitis (PMID 12109293). This sits in an older tradition of Soviet and post-Soviet work that framed DSIP as a stress-limiting or adaptogenic factor and tested it across organ-injury models. Readers should note the practical limits: the full text is not in English, the model was experimental rather than clinical, and the study is more than two decades old without, in this set, a modern replication (PMID 12109293).

Ageing and glucose metabolism

A 2004 paper in Advances in Gerontology addressed diabetes mellitus in the elderly and discussed geroprotective and antidiabetic properties of delta-sleep inducing peptide (PMID 15754961). This is the only paper in the set that frames the peptide around ageing and metabolic disease. It is a Russian-language publication in a specialist gerontology journal, and the description of "geroprotective and antidiabetic properties" should be read as the authors' framing of their own work rather than as a replicated, quantified clinical outcome (PMID 15754961).

Claimed benefits with little or no support in this evidence set

Several outcomes circulate in popular discussion of DSIP that do not appear in the verified papers summarised here. Stating that plainly is part of describing the evidence:

• Fat loss or body-composition change. No paper in this set measured body weight, fat mass or lean mass as an outcome; the metabolic discussion available here concerns geroprotective and antidiabetic framing in an elderly diabetes context (PMID 15754961).
• Muscle growth or athletic performance. Not an outcome in any cited study; the closest functional measure is motor recovery after experimental stroke in rats (PMID 34500605).
• Growth hormone or testosterone effects. No endocrine outcome was measured in the studies cited on this page, including the sleep-model work (PMID 39444618).
• Chronic pain, opioid or alcohol withdrawal, and anxiety. These outcomes are absent from this citation set; the neurological endpoints available are seizure activity in a chemically induced rat model (PMID 17191662) and memory after hypoxic sleep disruption (PMID 30107169).
• General "better sleep" in healthy adults. The sleep work here used a chemically induced insomnia mouse model (PMID 39444618) and a high-altitude animal model (PMID 30107169), neither of which enrolled healthy human sleepers.

Adverse Events and Tolerability: What Studies Report

The papers collected here were designed around efficacy endpoints, and their titles and abstract-level scope centre on outcomes such as motor recovery after focal stroke (PMID 34500605), infarct size during reperfusion (PMID 33918965) and efficacy in an insomnia model (PMID 39444618) rather than on systematic safety monitoring. Nothing in this set constitutes a human safety dataset: there is no controlled clinical trial, no pharmacovigilance series and no long-term toxicology report among the cited papers (PMID 17191662, PMID 15754961). Absence of reported harms in efficacy-focused animal experiments is not evidence of safety in people.

How to read this literature critically

1. Check the species. Mice and rats dominate: Sprague-Dawley rats in the stroke and cardiac work (PMID 34500605, PMID 33918965) and mice in the insomnia model (PMID 39444618).
2. Check the molecule. Phosphorylated DSIP (PMID 30107169), a fusion peptide (PMID 39444618) and a DSIP-like KND analogue (PMID 33918965) are not interchangeable with the native sequence.
3. Check the model's relevance. Chemically provoked seizures (PMID 17191662), serotonin-depletion insomnia (PMID 39444618) and induced pancreatitis (PMID 12109293) are simplified stand-ins for complex human conditions.
4. Check replication. Most domains above rest on a single paper, and several are decades old with no English full text (PMID 12109293, PMID 15754961).

Summary of the evidence base

Across the papers cited on this page, the study reported outcomes fall into a few narrow clusters: sleep and sleep-linked memory in rodent models using modified peptides (PMID 30107169, PMID 39444618), acute ischaemic injury in rats and mice (PMID 34500605, PMID 33918965), provoked seizures (PMID 17191662), experimental pancreatitis (PMID 12109293) and an ageing-and-diabetes discussion (PMID 15754961). Researchers working in these areas described directional effects in their models; none of this set establishes efficacy, dosing or safety for human use. Anyone weighing this material should do so with a licensed physician and with the preclinical status of the evidence in full view.

References

• Pichia pastoris secreted peptides crossing the blood-brain barrier and DSIP fusion peptide efficacy in PCPA-induced insomnia mouse models (Frontiers in Pharmacology, 2024)
• Delta Sleep-Inducing Peptide Recovers Motor Function in SD Rats after Focal Stroke (Molecules, 2021)
• DSIP-Like KND Peptide Reduces Brain Infarction in C57Bl/6 and Reduces Myocardial Infarction in SD Rats When Administered during Reperfusion (Biomedicines, 2021)
• Phosphorylated delta sleep inducing peptide restores spatial memory and p-CREB expression by improving sleep architecture at high altitude (Life Sciences, 2018)
• Valproate and delta-sleep peptide display high efficacy against metaphit-induced audiogenic seizure in rats (Acta Physiologica Hungarica, 2006)
• Diabetes mellitus in elderly: geroprotective and antidiabetic properties of delta-sleep induced peptide (Advances in Gerontology, 2004)
• Pharmacological efficacy of delta sleep-inducing peptide in experimental acute pancreatitis (Eksperimental'naia i klinicheskaia farmakologiia, 2002)